An international clinical trial, led in the UK by Swansea’s Joint Clinical Research Facility (JCRF), has found that ...

Adults with chronic kidney disease and type 2 diabetes had slower kidney function decline with a combination of the ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ ...

Novo Nordisk is making a strategic push into India's weight-loss market to secure its position ahead of competition from ...

Novo Nordisk NVO and Viking Therapeutics VKTX have emerged as notable players in the obesity space. A market leader in the GLP-1 space, Novo Nordisk markets its semaglutide drugs under brand names ...

March is National Kidney Month – a time to raise awareness and learn more about kidney health and kidney disease ... Richard Pratley, MD is a paid Novo Nordisk, Inc. spokesperson.

UBT251 has been approved for U.S. clinical trials for adult type 2 diabetes, overweight or obesity, and chronic kidney disease. The announcement came as Novo Nordisk announced it was expanding ...

‘Address unmet needs in serious chronic diseases’ Martin Holst Lange, Executive Vice President, Development, Novo Nordisk ... liver, and kidney disease. Same thing for amacretin,” Lange ...

EXTON, PA, Feb. 05, 2025 (GLOBE NEWSWIRE) -- As chronic kidney disease (CKD ... following the FDA’s recent label expansion of Novo Nordisk’s Ozempic® to include CKD benefits, reinforcing ...